Clinical Trial Update: Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of everolimus for relapsed/refractory germ cell cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Germ Cell Cancer
• Testicular Cancer

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Hannover Medical School | Conditions: Testicular Cancer, Germ Cell Cancer | Phase 2 | Status: COMPLETED